DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Has $1.96 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 56.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,541 shares of the biotechnology company’s stock after selling 7,072 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in United Therapeutics were worth $1,955,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics during the 4th quarter worth $25,000. Dunhill Financial LLC grew its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares in the last quarter. Millstone Evans Group LLC bought a new position in United Therapeutics during the fourth quarter worth about $67,000. MassMutual Private Wealth & Trust FSB raised its stake in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares in the last quarter. Finally, Natixis bought a new stake in United Therapeutics in the 4th quarter valued at about $85,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $300.93, for a total value of $3,310,230.00. Following the transaction, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at approximately $11,068,506.33. This represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 75,500 shares of company stock valued at $24,245,880. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on UTHR. Wells Fargo & Company reiterated an “equal weight” rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley lifted their price objective on United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a report on Thursday, May 1st. HC Wainwright reissued a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research note on Thursday, May 1st. Finally, StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $392.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $301.42 on Friday. United Therapeutics Co. has a one year low of $263.56 and a one year high of $417.82. The company has a market cap of $13.60 billion, a price-to-earnings ratio of 13.24, a PEG ratio of 0.97 and a beta of 0.58. The firm has a 50 day simple moving average of $300.53 and a 200 day simple moving average of $342.07.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.17 EPS. As a group, analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.